AU2020381775B2 - Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification - Google Patents

Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification

Info

Publication number
AU2020381775B2
AU2020381775B2 AU2020381775A AU2020381775A AU2020381775B2 AU 2020381775 B2 AU2020381775 B2 AU 2020381775B2 AU 2020381775 A AU2020381775 A AU 2020381775A AU 2020381775 A AU2020381775 A AU 2020381775A AU 2020381775 B2 AU2020381775 B2 AU 2020381775B2
Authority
AU
Australia
Prior art keywords
compound
weeks
calcification
aspects
inositol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020381775A
Other languages
English (en)
Other versions
AU2020381775A1 (en
Inventor
Miquel David FERRER REYNÉS
Joan PERELLÓ BESTARD
Carolina Salcedo Roca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vifor International AG
Original Assignee
Vifor International AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vifor International AG filed Critical Vifor International AG
Publication of AU2020381775A1 publication Critical patent/AU2020381775A1/en
Application granted granted Critical
Publication of AU2020381775B2 publication Critical patent/AU2020381775B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/177—Esters of thiophosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2020381775A 2019-11-11 2020-11-10 Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification Active AU2020381775B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382990.0 2019-11-11
EP19382990.0A EP3818983A1 (en) 2019-11-11 2019-11-11 Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
PCT/EP2020/081674 WO2021094331A1 (en) 2019-11-11 2020-11-10 Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification

Publications (2)

Publication Number Publication Date
AU2020381775A1 AU2020381775A1 (en) 2022-04-14
AU2020381775B2 true AU2020381775B2 (en) 2026-03-26

Family

ID=68610132

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020381775A Active AU2020381775B2 (en) 2019-11-11 2020-11-10 Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification

Country Status (10)

Country Link
US (2) US20220339171A1 (cg-RX-API-DMAC10.html)
EP (2) EP3818983A1 (cg-RX-API-DMAC10.html)
JP (1) JP7808029B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220099957A (cg-RX-API-DMAC10.html)
CN (2) CN114585367A (cg-RX-API-DMAC10.html)
AU (1) AU2020381775B2 (cg-RX-API-DMAC10.html)
CA (1) CA3156023A1 (cg-RX-API-DMAC10.html)
IL (1) IL292118B2 (cg-RX-API-DMAC10.html)
MX (1) MX2022004971A (cg-RX-API-DMAC10.html)
WO (1) WO2021094331A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021003653A (es) 2018-10-11 2021-06-23 Sanifit Therapeutics S A Inositol fosfatos para el tratamiento de calcificacion ectopica.
CN113712976B (zh) * 2021-10-21 2023-02-24 中国人民解放军海军军医大学 小分子化合物肌醇六磷酸酯钠水合物在制备抗SARS-CoV-2药物中的应用
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs
US20250217970A1 (en) * 2023-12-28 2025-07-03 Case Western Reserve University Risk prediction of heart failure

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271915A1 (en) * 2013-03-15 2014-09-18 Laboratoris Sanifit, S.L. Use of derivatives containing c-o-p bonds in patients with kidney failure
EP2974714A1 (en) * 2013-03-15 2016-01-20 Laboratorios Sanifit, S.L. Use of derivatives with c-o-p bonds in patients with renal failure

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
CA2132012C (en) 1992-03-25 2003-04-22 John W. Shell Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
WO2002096404A1 (en) 2001-05-29 2002-12-05 Depomed Development Ltd Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
MX347723B (es) 2011-09-29 2017-05-10 Eth Zuerich Compuestos farmaceuticos para usarse en la terapia de infeccion por clostridium difficile.
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
SMT202100406T1 (it) 2015-12-11 2021-09-14 Eth Zuerich Derivati di inositolo per l'uso nella cristallizzazione patologica
ES2762984T3 (es) 2015-12-11 2020-05-26 Eth Zuerich 4,6-di-(O-tiofosfato)-inositol-1,2,3,5-tetra-O-sulfato para la infección por C. difficile

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271915A1 (en) * 2013-03-15 2014-09-18 Laboratoris Sanifit, S.L. Use of derivatives containing c-o-p bonds in patients with kidney failure
EP2974714A1 (en) * 2013-03-15 2016-01-20 Laboratorios Sanifit, S.L. Use of derivatives with c-o-p bonds in patients with renal failure

Also Published As

Publication number Publication date
IL292118B2 (en) 2026-08-01
CA3156023A1 (en) 2021-05-20
EP3818983A1 (en) 2021-05-12
CN114585367A (zh) 2022-06-03
KR20220099957A (ko) 2022-07-14
US20250295676A1 (en) 2025-09-25
JP2023500020A (ja) 2023-01-04
US20220339171A1 (en) 2022-10-27
AU2020381775A1 (en) 2022-04-14
JP7808029B2 (ja) 2026-01-28
CN122080055A (zh) 2026-05-26
IL292118B1 (en) 2026-04-01
MX2022004971A (es) 2022-06-08
IL292118A (en) 2022-06-01
WO2021094331A1 (en) 2021-05-20
EP4058030A1 (en) 2022-09-21

Similar Documents

Publication Publication Date Title
US20250295676A1 (en) Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
US20240066042A1 (en) Use of derivatives containing c-o-p bonds in patients with kidney failure
JP6863618B2 (ja) 腎不全を患っている患者におけるｃ−ｏ−ｐ結合を含む誘導体の使用
US20230248749A1 (en) Inositol phosphate compounds for use in increasing tissular perfusion
US12594290B2 (en) IP and IP analogs dosage regimens for the treatment of ectopic calcifications
RU2832087C1 (ru) Соединения инозитолфосфата для применения в лечении, замедлении прогрессирования или предупреждении сердечно-сосудистой кальцификации
US20090110720A1 (en) Use of compounds for the prevention of drug-induced cell toxicity
HK40066584A (en) Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
HK40051461A (en) Inositol phosphate compounds for use in increasing tissular perfusion
JP5485704B2 (ja) 骨吸収と骨形成の不均衡を是正するための方法ならびにキット及び組成物
WO2025162971A1 (en) Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2023076329A1 (en) Compositions and methods for cancer therapy
HK40061817A (en) Use of derivatives with c-o-p bonds in patients with renal failure
BR112021006004B1 (pt) Uso de inositol hexafosfato

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: VIFOR (INTERNATIONAL) LTD.

Free format text: FORMER APPLICANT(S): SANIFIT THERAPEUTICS, S.A.

FGA Letters patent sealed or granted (standard patent)